Four 20 Pharma

Medical Cannabis Manufacturing420pharma.de

Four 20 Pharma GmbH is an EU-GMP- and GDP-certified German producer, importer, and wholesaler of medical cannabis flowers and full-spectrum extracts, distributing to pharmacies nationwide via physician prescriptions. It is a wholly-owned subsidiary of Curaleaf Holdings since April 2026.

Company typePrivate
Founded2018
HeadquartersPaderborn, Germany
Headcount11–50
GTM typeB2B
OfferingHardware or Manufacturing

What Four 20 Pharma does

Four 20 Pharma GmbH is a Paderborn-headquartered, EU-GMP- and GDP-licensed German manufacturer, importer, and wholesaler of medical cannabis, founded in 2018. The company's core portfolio consists of dried cannabis flowers produced under GACP-compliant controlled indoor cultivation and a 420 Cannabisextrakt line of full-spectrum extracts offered in four THC/CBD ratios (10/10, 25/25, 20/0, 0/50), supplemented by the QMID closed inhalation system and PIEX crude extracts through a partnership with Becanex. A three-stage Ph.Eur.-compliant laboratory testing protocol (at supplier, on import per Annex 21, and post-packaging) underpins product release, and operations are covered by a stack of German pharmaceutical licenses (§52a AMG wholesale, §3 BtMG narcotics, §13 AMG manufacturing, §7 AMG/§1 AMRadV irradiation). The company also runs the Four 20 Origins seeds sub-brand, the Four 20 Fam Shop merchandise line, and a free holographic patient identification card.

The business operates as a B2B distributor to German pharmacies via prescription; patient access is mediated entirely through prescribing physicians and dispensing pharmacies. Distribution is conducted through temperature-controlled direct delivery to pharmacies, an online pharmacy shop (420pharma-shop.de), and a DocCheck-gated professional portal providing Fachinformationen, CoA downloads, and training to doctors and pharmacists. Pricing is quote-based and not publicly disclosed because sales are prescription-mediated.

Following Curaleaf Holdings' initial majority investment in 2022 and the buyout of the remaining 45% stake completed on April 30, 2026, Four 20 Pharma is now a wholly-owned subsidiary of the US cannabis MSO, with Curaleaf cultivation in Portugal and Canada feeding the German distribution base. The company has signaled European expansion into the UK and Poland, complements its distribution with a marketing-heavy presence across medical congresses, sports sponsorships (SC Paderborn 07, Kölner Haie), and the ENDLICH Initiative, and maintains BSFZ Seal-recognized in-house research activity.

Four 20 Pharma firmographics

Firmographics

Name: Four 20 Pharma
Legal name: Four 20 Pharma GmbH
Website: https://420pharma.de
Company type: Private
Founded year: 2018
Operating status: Operating
Headcount range: 11–50 employees
Short description: Four 20 Pharma GmbH is an EU-GMP- and GDP-certified German producer, importer, and wholesaler of medical cannabis flowers and full-spectrum extracts, distributing to pharmacies nationwide via physician prescriptions. It is a wholly-owned subsidiary of Curaleaf Holdings since April 2026.
Ownership category
akta.pro rank

Four 20 Pharma industry classification

Industry

Product category: Medical Cannabis Manufacturing
NAICS: Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)
SIC: Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry: Medical Cannabis Dispensaries (CRANAFAB)
akta.pro secondary industry: Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)

Keywords

Medical cannabis
Pharmaceutical manufacturing
Cannabis wholesale distribution
GMP-certified production
EU-GDP supply

Where Four 20 Pharma is headquartered

Location

Headquarters

HQ city: Paderborn
HQ country: Germany
HQ region: Europe

Offices1 record

Markets served

Four 20 Pharma business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

Medical Cannabis Product Sales: Revenue generated from the sale of medical cannabis flowers and full-spectrum cannabis extracts to pharmacies. Products are sold B2B through pharmacy orders, with distribution facilitated through the company's pharmacy shop (420pharma-shop.de). Medical professionals prescribe products to patients who then obtain them from pharmacies.

Pricing tiers

Model	Billing	Price
Other	Pay-as-you-go	B2B pharmacy pricing - quote-based for medical cannabis products

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Four 20 Pharma product offering

Product offering

Core offering

Four 20 Pharma GmbH is an EU-GMP and GDP licensed German manufacturer, importer, and wholesaler of medical cannabis flowers and full-spectrum extracts. It produces and distributes the 420 Cannabisextrakt line (full-spectrum THC/CBD extracts in ratios of 10/10, 25/25, 20/0, and 0/50) and dried cannabis flowers, supplied exclusively to licensed pharmacies that dispense them to patients on prescription. The company also offers the QMID closed inhalation system co-developed with Becanex and PIEX crude extracts through the same partner relationship.

Product overview

Four 20 Pharma is a certified manufacturer, importer, and wholesaler of medical cannabis products based in Paderborn, Germany. The company operates a multi-product portfolio consisting of medical cannabis flowers (dried cannabis buds) and full spectrum cannabis extracts (420 Cannabisextrakte product line with various THC/CBD ratios including 10/10, 25/25, 20/0, and 0/50 formulations). Additionally, the company offers the QMID closed inhalation system for controlled cannabis dosing developed with partner Becanex, and provides a free patient card service for verification purposes. Products are distributed exclusively through pharmacies via prescription. The company is fully integrated along the supply chain from cultivation through GMP-compliant processing to pharmacy delivery.

Differentiator

Problem solved

Functional benefit

Brands

Four 20 Origins: Cannabis seeds shop offering genetics and seeds products.
Four 20 Fam Shop

Products and services

Medical Cannabis Flowers Dried cannabis flowers produced under EU-GMP conditions by Four 20 Pharma, distributed through licensed German pharmacies to patients holding valid medical prescriptions. Intended for medical cannabis therapy with full pharmaceutical-grade quality documentation.
420 Cannabisextrakt Full Spectrum Extracts (10/10, 25/25, 20/0, 0/50 THC/CBD ratios) Full-spectrum cannabis extract product line offered by Four 20 Pharma with multiple cannabinoid ratios: 10/10 (10% THC / 10% CBD), 25/25 (25% THC / 25% CBD), 20/0 (20% THC / 0% CBD), and 0/50 (0% THC / 50% CBD). Used by physicians and pharmacies for targeted medical cannabis therapy depending on patient clinical need.
QMID Closed Inhalation System Closed inhalation system co-developed with Becanex that provides controlled dosing for medical cannabis extracts; addresses technical and pharmaceutical integration of cannabis extracts into modern application forms for patients and prescribers.
PIEX Crude Extracts Raw cannabis extracts co-developed with Becanex for processing into finished medical cannabis products, supporting the company's vertically integrated extract supply chain.
Four 20 Pharma Patient Card Free personalized patient identification card that verifies medical cannabis patient status via holographic security; provided to patients to simplify proof of medication eligibility, supported by a Kanna Medics partnership for application assistance.

Quantifiable outcome

Germany market leader in medical cannabis quality and delivery capacity
+1 more outcomes

Companies that use Four 20 Pharma

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Four 20 Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Four 20 Pharma partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

Kanna MedicscoreStrategic or Co-development PartnerPartnership with Kanna Medics for patient application assistance. Kanna Medics provides an easy-to-use application tool for patients to complete with their doctors for medical cannabis therapy access.
SC Paderborn 07flagshipGTM or Marketing PartnerMain and shirt sponsor of SC Paderborn 07 since 2023/2024 season - first professional German soccer club to feature medical cannabis company on jersey. Partnership focused on education, innovation, and public awareness about medical cannabis.
Compound GeneticscoreTechnology or IntegrationPartnership for cannabis genetics at events like Mary Jane Berlin 2026. Focus on high-quality genetics, pharmaceutical quality standards, and professional flower photography for variety understanding and quality assurance.
BecanexcoreTechnology or IntegrationPartnership for cannabis extract technology and inhalation systems. Becanex contributes expertise in PIEX crude extracts and QMID closed inhalation system, addressing technical and pharmaceutical integration of cannabis extracts into modern application forms.
Sanity GroupcoreStrategic or Co-development PartnerCo-founded ENDLICH Initiative e.V. together with Sanity Group for education and fact-based exchange about medical cannabis. Campaign features public projections in Berlin with personalities from medicine, sports, and culture.
PLANT-MY-TREE®minorOthersClimate protection partnership with PLANT-MY-TREE® for reforestation projects to offset CO2 emissions in Germany. Projects include forest conversion and protection with high biodiversity and 99-year minimum project periods.
ENDLICH Initiative e.V.coreStrategic or Co-development PartnerInitiative for removing taboos and factual discussion about medical cannabis, working with personalities from medicine, sports, and culture for open dialogue about medical cannabis benefits and therapy options.
Golden Leaf GalaminorGTM or Marketing PartnerAnnual industry event at Flora Köln featuring medical cannabis pioneers from medicine, research, and politics. Four 20 Pharma sponsors the event which includes lectures, discussions, and a show program with proceeds going to charitable causes.
FussicampsminorOthersSupport for the Fussicamps initiative around Holger Gehrke, providing football training and community experiences for children and youth. Includes procurement of materials, organization of training camps, and PR support.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Four 20 Pharma competitors and assessment

Company assessment

Direct peers

Demecan: German vertically integrated medical cannabis producer and wholesaler supplying pharmacies with flowers and extracts. Competes head-to-head with Four 20 Pharma on EU-GMP-certified product quality and pharmacy relationships in Germany.
Sanity Group: Berlin-based medical cannabis producer and distributor with EU-GMP operations targeting the same German pharmacy channel. Direct competitor and co-founder of the ENDLICH Initiative with Four 20 Pharma, indicating overlapping GTM and customer base.
Bloomwell Group: Frankfurt-based German medical cannabis platform combining wholesale distribution with telemedicine prescribing. Targets the same doctors, pharmacies, and patients as Four 20 Pharma's channel in Germany.

Broad incumbents

Stada Arzneimittel: Major German generics and specialty pharma company with a growing medical cannabis portfolio. Competes with Four 20 Pharma via established pharmacy sales infrastructure and broader pharma credibility.
Canopy Growth: Global cannabis operator with European medical cannabis presence including Germany. Overlaps with Four 20 Pharma on pharmaceutical-grade cannabis flowers and extracts sold through German pharmacies.
Aurora Cannabis: Canadian licensed producer with established EU-GMP operations and German medical cannabis distribution. Competes with Four 20 Pharma for pharmacy contracts and prescriber relationships across Germany.
Tilray Brands: Canadian-headquartered global cannabis company with significant German medical cannabis operations. Competes in the same pharmacy distribution channel and benefits from similar EU-GMP capabilities but at much greater scale and global footprint.

Regional players

Cansativa: German cannabis platform focused on B2B pharmacy distribution and a marketplace model. Operates in the same pharmacy channel and competes for shelf share with EU-GMP-certified producers including Four 20 Pharma.
Nimbus Health: German medical cannabis distributor supplying pharmacies with flowers and extracts. Directly comparable wholesale business model and pharmacy-customer base to Four 20 Pharma.

Others

Becanex: Technology partner of Four 20 Pharma providing PIEX crude extracts and the QMID closed inhalation system. Included as a peer because it is a directly adjacent input and device supplier into the same medical cannabis value chain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Four 20 Pharma compliance and trust

Trust signal

Compliance8 records

Four 20 Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Four 20 Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Four 20 Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Four 20 Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Four 20 Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Four 20 Pharma

What does Four 20 Pharma do?

Is Four 20 Pharma a public or private company?

Four 20 Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Four 20 Pharma founded?

Four 20 Pharma was founded in 2018. It employs 11 to 50 people.

Where is Four 20 Pharma based?

Four 20 Pharma is headquartered in Paderborn, Germany, in the Europe region.

How does Four 20 Pharma make money?

One revenue line is on record: medical Cannabis Product Sales.

Who are Four 20 Pharma's main competitors?

Direct peers on record are Demecan, Sanity Group and Bloomwell Group. Broad incumbents are Stada Arzneimittel, Canopy Growth, Aurora Cannabis and Tilray Brands. Regional players are Cansativa and Nimbus Health. Becanex is listed as an others.

Does Four 20 Pharma have an API?

No public API is recorded for Four 20 Pharma.

What industry is Four 20 Pharma in?

Four 20 Pharma's product category is Medical Cannabis Manufacturing. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAFAG, Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail). Its NAICS code is 424210 and its SIC code is 5122.